Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer.

Only a small proportion of women who are exposed to infection with high-risk human papillomavirus (HR-HPV) progress to persistent infection and develop cervical cancer (CC). The immune response and genetic background of the host may affect the risk of progression from a HR-HPV infection to lesions and cancer. However, to our knowledge, no studies has been conducted to evaluate the relationship between variability of human leukocyte antigens (HLA) genes and serum cytokine expression in this pathology. In the current study, we examined the associations of HLA alleles and haplotypes including Class I (HLA-A, -B and -C) and II (HLA-DRB1, -DQA1 and -DQB1) with serum levels of cytokines interleukin (IL)-6, tumor necrosis factor-α (TNF-α), IL-10 and IL-17 as well as risks of HPV infections, lesions and CC among admixed Brazilian women. HLA polymorphisms were associated with an increased risk or protection from HPV, lesions and CC. Additionally, we demonstrated a potential association of a HLA class I haplotype (HLA-B*14-C*08) with higher IL-10 cytokine serum levels in cervical disease, suggesting an association between HLA class I and specific cytokines in cervical carcinogenesis. However, larger studies with detailed HPV types coupled with genetic data are needed to further evaluate the effects of HLA and CC by HPV genotype.

Association of HLA-G 3'UTR polymorphisms and haplotypes with severe sepsis in a Brazilian population.

BACKGROUND: The human leukocyte antigen G (HLA-G) is a molecule involved in immune system modulation, acting in the maintenance of a state of immune tolerance. Some polymorphisms in the HLA-G gene 3' untranslated region (3'UTR) were associated to distinct levels of HLA-G expression and to sepsis development. In the present study, haplotypes and polymorphisms of the HLA-G 3'UTR were analyzed in Brazilian septic patients. METHODS: The HLA-G 3'UTR was amplified by PCR, sequenced and eight polymorphisms were genotyped (the 14bp insertion/deletion, +3003T/C, +3010C/G, +3027A/C, +3035C/T, +3142G/C, +3187A/G and+3196C/G) in DNA samples from septic patients (with severe sepsis or septic shock) and controls. The haplotypes were inferred and association tests were performed through Chi square test and binary logistic regression. RESULTS: The+3027AC genotype was associated asa risk factor to sepsis development (OR 3.17, PBonferroni 0.048). Further, the presence of the UTR-7 haplotype (OR 2.97, PBonferroni 0.018), and of 14bp-Ins_+3142G_+3187A haplotype (OR 2.39, PBonferroni 0.045) were associated with sepsis, conferring susceptibility. CONCLUSION: Our data confirm an important role of HLA-G 3'UTR polymorphisms in the development of severe forms of sepsis (severe sepsis and septic shock). The genotyping of HLA-G genetic variants and haplotypes could be useful as a prediction tool of increased risk to severe sepsis.

C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels.

The T rare allele of +1444CT (rs1130864) polymorphism of C-reactive protein (CRP) has been associated with increased CRP levels in some inflammatory conditions, but its role on systemic lupus erythematosus (SLE) susceptibility and on CRP levels in SLE patients remains uncertain. The objective of the study was to evaluate the association between the rs1130864 CRP polymorphism with SLE susceptibility, disease activity, and CRP levels in SLE Brazilian patients. The study enrolled 176 SLE patients and 137 controls. SLE disease activity was assessed using the SLE Disease Activity Index (SLEDAI). The rs1130864 CRP polymorphism was determined using polymerase chain reaction and restriction fragment length polymorphism. SLE patients presented higher body mass index (p = 0.046) and CRP levels (p = 0.017) than controls. The genotype and allele frequencies of patients differed from controls [CC vs. CT = odds ratio (OR) 1.730, 95% confidence interval (CI) 1.068-2.803, p = 0.035; CC vs. TT = OR 3.667, 95% CI 1.410-9.533, p = 0.009; C vs. T = OR 1.883, 95% CI 1.299-2.728, p = 0.001)]. Patients carrying the T allele presented higher CRP levels (p = 0.009), were more frequent Caucasians (p = 0.018), and with no use of immunosuppressive treatment (p = 0.004) than those carrying the C allele. However, the SLEDAI and anti-double-stranded DNA positivity did not differ from those carrying T vs. C allele (p = 0.595 and p = 0.243, respectively). The rs1130864 CRP polymorphism was associated with SLE susceptibility and CRP levels, but not with disease activity, suggesting that this polymorphism may play a role in the pathophysiology of SLE through increasing the CRP that, probably, plays an inflammatory role in SLE pathophysiology.

Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome.

The aim of this study was to investigate whether vitamin D deficiency (VDD) is associated with acute ischemic stroke, inflammatory markers, and short-term outcome. 168 acute ischemic stroke patients and 118 controls were included. The modified Rankin Scale (mRS) was applied up to 8 h of admission (baseline) and after three-months follow-up, and blood samples were obtained up to 24 h of admission to evaluate serum levels of 25-hydroxivitamin D [25(OH)D] and inflammatory markers. Vitamin D levels classified the individuals in sufficient (VDS ≥ 30.0 ng/mL), insufficient (VDI 20.0-29.9 ng/mL), and deficient (VDD < 20.0 ng/mL) status. Patients had lower levels of 25(OH)D, higher frequency of VDD (43.45% vs. 5.08%, OR: 16.64, 95% CI: 5.66-42.92, p < 0.001), and higher inflammatory markers than controls (p < 0.05). Patients with VDD showed increased high sensitivity C-reactive protein (hsCRP) levels than those with VDS status (p = 0.043); those with poor outcome presented with lower 25(OH)D levels than those with good outcome (p = 0.008); moreover, 25(OH)D levels were negatively correlated with mRS after three-months follow-up (r = -0.239, p = 0.005). The associations between VDD and higher hsCRP levels and between 25(OH)D levels and poor outcome at short-term in acute ischemic stroke patients suggest the important role of vitamin D in the inflammatory response and pathophysiology of this ischemic event.

Influence of Insulin Resistance and TNF-α on the Inflammatory Process, Oxidative Stress, and Disease Activity in Patients with Rheumatoid Arthritis.

The aim of this study was to evaluate the involvement of TNF-α and insulin resistance (IR) in the inflammatory process, oxidative stress, and disease activity in patients with rheumatoid arthritis (RA). This cross-sectional study included 270 subjects (control group, n = 97) and RA patients (n = 173). RA patients were divided into four groups: the first group without IR and not using antitumor necrosis factor-α (TNF-) (G1, IR- TNF-); the second group without IR and using anti-TNF-α (G2, IR- TNF+); the third group with IR and not using anti-TNF-α (G3, IR+ TNF-); and the fourth group with IR and using anti-TNF-α (G4, IR+ TNF+). G3 and G4 had higher (p < 0.05) advanced oxidation protein products (AOPPs) and oxidative stress index (OSI) compared to G1. G4 group presented higher (p < 0.05) AOPPs and OSI than G2. TRAP was significantly lower in G3 compared to G1. Plasma TNF-α levels were significantly higher in G4 and G2 compared to G1 (p < 0.0001) and G3 (p < 0.0001 and p < 0.01, resp.). The presence of insulin resistance was robustly associated with both oxidative stress and TNF-α levels. More studies are warranted to verify if IR can be involved in therapeutic failure with TNF-α inhibitors. This trial is registered with Brazilian Clinical Trials Registry Register number RBR-2jvj92.

CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients.

The role of CCR5Δ32 (rs333) polymorphism in the pathogenesis of systemic lupus erythematosus (SLE) has been evaluated worldwide. The aim of this study was to determine the association between CCR5Δ32 polymorphism with the susceptibility to SLE and the activity of disease in female Southern Brazilian patients. The study enrolled 169 female SLE patients and 132 unrelated female healthy individuals. Baseline clinical, laboratorial characteristics, and the SLE activity (determined using the SLEDAI) were evaluated according to the CCR5Δ32 genotypes. The CCR5Δ32 polymorphism was determined from genomic DNA using a polymerase chain reaction. The frequencies of the genotypes CCR5/CCR5, CCR5/CCR5Δ32, and CCR5Δ32/CCR5Δ32 were 87.6, 11.8, and 0.6 %, respectively, among the patients and 96.2, 3.8, and 0.0 %, respectively, among the controls [CCR5/CCR5 vs. CCR5/CCR5Δ32 + CCR5Δ32/CCR5Δ32: p = 0.0081, odds ratio 3.604 (95 % confidence interval 1.321-9.4836)]. The frequencies of the CCR5 and the CCR5Δ32 alleles were 93.2 and 6.8 % among the patients, and 98.1 and 1.9 % among the controls, respectively (p = 0.0047, OR 3.758, 95 % CI 1.409-10.80). Patients carrying the genotypes with the CCR5Δ32 allele presented earlier age of onset of disease (p = 0.0293) and higher levels of anti-dsDNA (p = 0.0255) than those carrying the wild-type genotype. When the analysis was adjusted for ethnicity, only the age at onset of disease remained significant (p > 0.05). The results suggest that the CCR5Δ32 polymorphism might be associated with SLE genetic predisposition among female Brazilian patients and the age at onset of the disease; however, this genetic variant was not associated with the activity of SLE in this population.

Avaliação do polimorfismo genético pvuII do receptor de lipoproteína de baixa densidade (RLDL) em pacientes com lúpus eritematoso sistêmico / Evaluation of genetic polymorphism pvuII of low density lipoprotein receptor (LDLR) in patients with systemic lupus erythematosus

Lúpus Eritematoso Sistêmico (LES) é uma doença inflamatória crônica do tecido conjuntivo, relacionada a alterações do perfil lipídico e ao metabolismo de lipoproteínas. Estudos mostram que o polimorfismo genético PvuII do receptor de lipoproteína de baixa densidade (RLDL) está associado às diferentes concentrações de lipoproteína de baixa (LDL) na população em geral. O presente estudo avaliou o polimorfismo genético PvuII do RLDL e o perfil lipídico em pacientes com LES da população sul brasileira. Foram incluídos 72 pacientes com LES e 154 doadores de sangue. Pacientes com LES apresentaram elevados níveis séricos de triglicerídeos (TG) quando comparados com o grupo controle (p<0,0001). Semelhantemente, pacientes com LES ativo apresentaram maiores níveis de TG quando comparados a pacientes com LES sem atividade da doença (p=0,0113). Em relação à frequência do polimorfismo genético PvuII do RLDL, 35 (48,6%) dos pacientes com LES apresentavam o genótipo P1P1, 32 (44,4%) o genótipo P1P2 e 5 (6,9%) o genótipo P2P2. Não foram encontradas diferenças nas frequências do genótipo P1P1 vs P1P2 e P1P1 vs P2P2 quando comparado entre pacientes com LES e controles (p>0,05). Pacientes com LES e genótipo P1P1 apresentaram uma tendência a ter valores mais elevados de TG quando comparados a pacientes com LES e genótipo P1P2+P2P2 (p=0,0687). Conclui-se que polimorfismos genéticos podem contribuir para o aumento de risco cardiovascular; no entanto,deve-se levar em consideração a complexidade dos componentes genéticos e da doença avaliada.Maiores investigações são necessárias para outros genes que possam estar envolvidos na alteração do perfil lipídico nesta população.

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of connective tissue related to changes in lipid profile and lipoprotein metabolism. Studies show that the genetic polymorphism of PvuII low density lipoprotein receptor (LDLR) is associated with different concentrations of low-density lipoprotein (LDL) in general population. The present study evaluated the genetic polymorphism of PvuII of LDLR and lipid profile in patients with SLE in southern Brazilian population. We included 72 patients with SLE and 154 blood donors. In assessing the lipid profile, SLE patients had elevated serum triglycerides (TG) levels compared with the control group (p <0.0001). Similarly, patients with active SLE have elevated TG levels when compared to patients without SLE disease activity (p = 0.0113). Regarding the frequency of genetic polymorphism of PvuII of LDLR, 35 (48.6%) patients with SLE had P1P1 genotype, 32 (44.4%) P1P2 genotype and 5 (6.9%) the P2P2 genotype. There were no differences in the genotype frequencies P1P1 vs P1P2 and P1P1vs P2P2 compared between SLE patients and controls (p>0.05). Patients with SLE and P1P1 genotype tended to have higher levels of TG compared with patients with SLE and P1P2 + P2P2 genotype (p = 0.0687). We conclude that genetic polymorphism may contribute to increased cardiovascular risk; however, the complexity of genetic components and disease evaluated should be taken into consideration. Further investigations are needed for other genes that may be involved in altering the lipid profile in this population.

Tumor necrosis factor beta NcoI polymorphism (rs909253) is associated with inflammatory and metabolic markers in acute ischemic stroke.

Polymorphisms in genes coding for pro-inflammatory molecules represent important factors for the pathogenesis and outcome of stroke. The aim of this study was to evaluate the relationship between the tumor necrosis factor beta (TNF-ß) NcoI (rs909253) polymorphism with inflammatory and metabolic markers in acute ischemic stroke. Ninety-three patients and 134 controls were included. The TNF-ß polymorphism was determined using PCR-RFLP with NcoI restriction enzyme. Stroke subtypes and neurological deficit score were evaluated. White blood cell counts, erythrocyte sedimentation rate (ESR), plasma levels of IL-6 and TNF-α, serum high sensitivity C-reactive Protein (hsCRP), serum lipid profile, plasma levels of glucose and insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) were determined. Stroke patients presented higher white blood cell counts, hsCRP, ESR, glucose, insulin, and HOMA-IR, and lower HDL cholesterol than controls (p < 0.01). There was no difference in genotypic and allelic frequency of TNF-ß NcoI polymorphism among patients and controls (p > 0.05). However, stroke patients carrying the TNFB2/B2 genotype presented higher levels of TNF-α, white blood cell counts, total cholesterol, LDL cholesterol, glucose, insulin, and HOMA-IR than those with other genotypes (p < 0.05). White blood cells, IL-6, hsCRP, and ESR were positively correlated with the neurological deficit of the patients (p < 0.05). Taken together, TNF-ß NcoI polymorphism, by itself, was not associated with increased susceptibility for stroke development. However, the homozygous genotype for the allele TNFB2 was associated with higher expression of classical inflammatory and metabolic markers of development and outcome of stroke than other genotypes. The identification of variant alleles might allow both better prediction of susceptibility for stroke as well the identification of novel stroke mechanisms that could be target to new therapeutic approaches. Stroke patients carrying the TNFB2 variant allele could have a beneficial effect with the anti-inflammatory therapies in the early inflammatory phase of stroke.

Serum levels of high sensitive C reactive protein in healthy adults from southern Brazil.

BACKGROUND: With the emergence of more sensitive assay techniques, it has been shown that C reactive protein (CRP) is present at low levels in the serum of all the clinically healthy individuals. OBJECTIVE: To determine the interval values of high-sensitivity CRP (hs-CRP) in healthy adults. METHODS: Serum hs-CRP level was evaluated in 176 healthy blood donors. RESULTS: The serum hs-CRP level ranged from <0.175 to 48.7 mg/l (median 1.2 mg/l); 127 (72.2%) individuals exhibited values ≥0.175 and <3.0 mg/l and 31 (17.6%) showed values >3.0 and ≤10.0 mg. Higher hs-CRP level was observed among the female than male (P = 0.0001), and among the older than the younger individuals (P = 0.0180). Individuals with body mass index ≥25.0 kg/m(2) exhibited higher hs-CRP level than those with normal weight (18.5-24.9 kg/m(2) ; P < 0.0005). When the participants were stratified into gender and low (≤24.9 kg/m(2) ) and high (≥24.9 kg/m(2) ) body mass index (BMI) groups, the gender difference in hs-CRP levels remained (female with low BMI vs. male with low BMI, P = 0.0221; female with high BMI vs. male with high BMI, P = 0.0001). CONCLUSION: Gender, age, and BMI influence serum hs-CRP level in healthy individuals and these variables should be considered for the interpretation of hs-CRP values. The results reinforce the importance in evaluating whether these differences in hs-CRP levels could contribute to alter the cardiovascular risk criteria and clinical outcomes, and whether hs-CRP thresholds for cardiovascular risk assessment should be adjusted for different gender and body mass index groups.

Association of tumor necrosis factor ß genetic polymorphism and sepsis susceptibility.

The association of the tumor necrosis factor ß (TNF-ß) Nco1 genetic polymorphism with susceptibility to sepsis was evaluated in 60 consecutive patients diagnosed with sepsis and in 148 healthy blood donors. Genomic DNA was extracted from peripheral blood cells and a 782 base-pair fragment of the TNF-ß gene was amplified by PCR. The PCR products were subjected to Nco1 restriction digestion and analysed by restriction fragment length polymorphism analysis. Tumor necrosis factor α (TNF-α) and the C-reactive protein (CRP) serum levels were also determined by ELISA and nephelometry, respectively. Among the septic patients, the allelic frequencies of TNFB1 and TNFB2 were 0.2833 and 0.7166, respectively, and they differed from those observed in the blood donors (p=0.0282). The TNFB2 allele frequency was higher in the septic patients than in the blood donors [odds ratio=1.65 (CI 95% 1.02-2.69), p=0.0315]. The TNF-α and CRP serum levels and the APACHE II and SOFA clinical scores did not differ in the patients with the TNFB1 or TNFB2 alleles (p>0.05). The results suggest that the TNFB2 allele is associated with susceptibility to sepsis, but it was not found to be associated with the immunological and clinical biomarkers of the disease.

A importância dos exames laboratoriais no monitoramento da doença de Graves e artrite reumatóide / The laboratorial tests and its importance in the clinical course of therapeutic monitoring in Graves' disease and rheumatoid arthritis

A auto-imunidade se manifesta quando ocorre uma falha nos mecanismos de auto-tolerância responsáveis pela discriminação entre o próprio e o não próprio, desencadeando uma resposta imune adaptativa específica contra os auto-antígenos. A doença de Graves (DG), uma doença auto-imune associada com atividade excessiva da tireóide, podendo vir associada a outras doenças auto-imunes endócrinas, como Diabetes mellitus tipo 1, e não endócrinas como Lupus Eritematoso Sistêmico (LES) ou Artrite Reumatóide (AR). As doenças auto-imunes são caracterizadas pela etiologia multifatorial, onde fatores genéticos, endócrinos, imunológicos, infecciosos, ambientais e emocionais contribuem para o desencadeamento e agravamento dos processos lesivos. Tem-se pesquisado cada vez mais a influência de fatores genéticos sobre o desenvolvimento de doenças auto-imunes e é neste contexto que se observa a forte associação do HLA-DR, tanto com DG como com AR. O presente trabalho tem como objetivo descrever as alterações laboratoriais observadas em uma paciente do sexo feminino, 22 anos, branca, com o diagnóstico das duas doenças auto-imunes de evolução crônica, a DG e AR, correlacionar os resultados laboratoriais com os sinais e sintomas clínicos apresentados e avaliar os exames laboratoriais realizados para o monitoramento clínico e terapêutico.